Your browser doesn't support javascript.
loading
Impact of pre-existing vascular disease on clinical outcomes.
Weight, Nicholas; Moledina, Saadiq; Zoccai, Giuseppe Biondi; Zaman, Sarah; Smith, Triston; Siller-Matula, Jolanta; Dafaalla, Mohamed; Rashid, Muhammad; Nolan, James; Mamas, Mamas A.
Afiliação
  • Weight N; Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, Stoke-on-Trent, UK.
  • Moledina S; Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, Stoke-on-Trent, UK.
  • Zoccai GB; Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
  • Zaman S; Mediterranea Cardiocentro, Napoli, Italy.
  • Smith T; Department of Cardiology, Westmead Hospital, Sydney, Australia.
  • Siller-Matula J; Westmead Applied Research Centre, University of Sydney, Sydney, Australia.
  • Dafaalla M; Department of Cardiology, Trinity Health System, Steubenville, Ohio, USA.
  • Rashid M; Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
  • Nolan J; Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Center for Preclinical Research and Technology (CEPT), Warsaw, Poland.
  • Mamas MA; Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, Stoke-on-Trent, UK.
Eur Heart J Qual Care Clin Outcomes ; 9(1): 64-75, 2022 12 13.
Article em En | MEDLINE | ID: mdl-35575608
ABSTRACT

AIMS:

Little is known about the outcomes and processes of care of patients with non-ST-segment myocardial infarction (NSTEMI) who present with 'polyvascular' disease. METHODS AND

RESULTS:

We analysed 287 279 NSTEMI patients using the Myocardial Ischaemia National Audit Project registry. Clinical characteristics and outcomes were analysed according to history of affected vascular bed-coronary artery disease (CAD), cerebrovascular disease (CeVD), and peripheral vascular disease (PVD)-with comparison to a historically disease-free control group, comprising 167 947 patients (59%). After adjusting for demographics and management, polyvascular disease was associated with increased likelihood of major adverse cardiovascular events (MACEs) [CAD odds ratio (OR) 1.06; 95% confidence interval (CI) 1.01-1.12; P = 0.02] (CeVD OR 1.19; 95% CI 1.12-1.27; P < 0.001) (PVD OR 1.22; 95% CI 1.13-1.33; P < 0.001) and in-hospital mortality (CeVD OR 1.24; 95% CI 1.16-1.32; P < 0.001) (PVD OR 1.33; 95% CI 1.21-1.46; P < 0.001). Patients without vascular disease were less frequently discharged on statins (PVD 88%, CeVD 86%, CAD 90%, and control 78%), and those with moderate [ejection fraction (EF) 30-49%] or severe left ventricular systolic dysfunction (EF < 30%) were less frequently discharged on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) (CAD 82%, CeVD 77%, PVD 77%, and control 74%). Patients with polyvascular disease were less likely to be discharged on dual antiplatelet therapy (DAPT) (PVD 78%, CeVD 77%, CAD 80%, and control 87%).

CONCLUSION:

Polyvascular disease patients had a higher incidence of in-hospital mortality and MACEs. Patients with no history of vascular disease were less likely to receive statins or ACE inhibitors/ARBs, but more likely to receive DAPT.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Inibidores de Hidroximetilglutaril-CoA Redutases / Infarto do Miocárdio Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Inibidores de Hidroximetilglutaril-CoA Redutases / Infarto do Miocárdio Idioma: En Ano de publicação: 2022 Tipo de documento: Article